Driehaus Capital Management LLC Abb Vie Inc. Transaction History

Driehaus Capital Management LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$159.82 - $182.1 $219,912 - $250,569	1,376 New	1,376 $250,000
Q2 2022 Aug 15, 2022	BUY	$137.62 - $174.96 $252,670 - $321,226	1,836 New	1,836 $281,000
Q4 2021 Feb 14, 2022	SELL	$107.43 - $135.93 $297,581 - $376,526	-2,770 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$106.4 - $120.78 $294,728 - $334,560	2,770 New	2,770 $299,000
Q4 2020 Feb 16, 2021	SELL	$80.49 - $108.67 $288,476 - $389,473	-3,584 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$85.91 - $100.83 $81,356 - $95,486	947 Added 35.91%	3,584 $314,000
Q2 2020 Aug 14, 2020	SELL	$73.37 - $98.18 $2,274 - $3,043	-31 Reduced 1.16%	2,637 $259,000
Q1 2020 May 15, 2020	BUY	$64.5 - $97.79 $172,086 - $260,903	2,668 New	2,668 $203,000
Q3 2018 Nov 14, 2018	SELL	$88.91 - $98.84 $208,405 - $231,680	-2,344 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$89.78 - $106.23 $13,826 - $16,359	-154 Reduced 6.16%	2,344 $217,000
Q1 2018 May 15, 2018	SELL	$92.01 - $123.21 $30,455 - $40,782	-331 Reduced 11.7%	2,498 $236,000
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $197,605 - $252,403	2,829	2,829 $251,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Driehaus Capital Management LLC with notifications on news.